FX06 is a naturally occurring peptide derived from the neo-N-terminus of fibrin (Bbeta(15-42)). It prevents leukocyte migration through the gap junctions of endothelial cells. FX06 has proven safe in acute... FX06 has proven safe in acute and subchronic toxicological studies and recently entered clinical development.
- Mechanism
- Curator reviewed
FX06 has a novel mechanism of action: it is a competitive inhibitor of the binding of fibrin E1 fragments to vascular endothelial (VE)-cadherin. Through this inhibition, it potently blocks the transmigration of inflammatory leukocytes through the endothelial barrier and prevents the downstream release of tissue-damaging mediators.
- Primary indication
- Investigated for use/treatment in cardiac reperfusion injury and myocardial infarction.Curator reviewed
Resolves to
What you can answer from here — as of April 02, 2025
Which drugs share a target with FX06, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account